The general public did not know much about mRNA vaccines a few months ago; now biotech firms like Moderna, BioNTech or CureVac have almost become household brand-names! We spoke this month with Sander Slootweg, Founder and Managing Partner of Forbion – one of the leading biotech investors in Europe. He told us about the incredible breakthrough life sciences have made in the last decades, how the European biotech ecosystem is reaching new milestones and why LPs are increasingly interested in this space.
Enjoy this May IPEM rendez-vous!
